



VIA HAND DELIVERY FEBRUARY 10TH, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: YOUNG et al.

Application Serial No.: 10/046,433

Art Unit: 1646

Filed: January 16, 2002

Examiner: O'Hara, E.

For: Human Tumor Necrosis Factor
Receptors TR13 and TR14

Attorney Docket No.: PF511P1

#6
Mg
2/24/03

Information Disclosure Statement Pursuant to 37 C.F.R. § 1.56

Commissioner for Patents.
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Applicants hereby direct the Examiner's attention to the references AA-EB listed on the attached revised Form PTO/SB/08.

Copies of references AA-EB were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/618,570 filed July 14, 2000, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the file of United States Patent Application Serial No. 09/618,570 for copies of references AA-EB.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of the present application are related to SEQ ID NOs:65680, 67837, 67878, 67920, 67983, 68255, and 181661 in copending U.S. Patent Application Serial No. 09/912,293 (reference AB), that SEQ ID NO:39 and the corresponding cDNA clone of the present application are related to SEQ ID NOs: 65680,

67837, 67878, 67920, 67983, 68255, 68349, and 181661 in copending U.S. Patent Application Serial No. 09/912,293, and that SEQ ID NO:60 and the corresponding cDNA clone of the present application are related to SEQ ID NOs:53053 and 227527 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached form PTO/SB/08 was previously submitted on December 11, 2001, by Applicants in connection with United States Patent Application Serial No. 09/618,570, as reference AB.

Applicants note that references AC, AD, and AW are not in the English language, however as required under 37 C.F.R. § 1.98(a)(3)(i), references AC, AD, and AW contain abstracts in the English language which explain the relevance of these documents. The relevance of reference AC is further indicated within reference BG. Furthermore, references AH and AI, which represent the German and International applications for the same subject matter, are not in the English language. However, as required under 37 C.F.R. § 1.98(a)(3)(i), reference AH contains an abstract in the English language, and the relevance of these documents is indicated in references BC and BD. Applicants further note that all non-English language references, AC, AD, AH, and AI, include nucleic acid and amino acid sequence information that does not require translation to the English language.

Applicants note that references AU, AV, AX and AZ are incomplete. Due to the excessive length of the sequence listings of these publications and so as not to overburden the Examiner and the Patent Office files, Applicants have previously submitted, as required under 37 C.F.R. § 1.98(a)(2)(ii), those portions of the sequence listings, and those Geneseq database entries (see references BC-BJ), which have caused said documents to be

listed in the Information Disclosure Statement, in connection with United States Patent Application Serial No. 09/618,570 on December 11, 2001.


Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

In accordance with 37 C.F.R. § 1.97(b)(3), since it is believed that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: February 10, 2003



Lin J. Hymel (Reg. No. 45,414)
Attorney for Applicants
Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

KKH/LJH/BM
Enclosures